ZIOPHARM Oncology (NASDAQ:ZIOP) Shares Gap Up to $4.89

Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) gapped up before the market opened on Thursday . The stock had previously closed at $4.78, but opened at $4.89. ZIOPHARM Oncology shares last traded at $5.22, with a volume of 4,606,098 shares traded.

Several brokerages recently weighed in on ZIOP. BidaskClub upgraded ZIOPHARM Oncology from a “hold” rating to a “buy” rating in a research report on Monday, February 25th. Lake Street Capital began coverage on ZIOPHARM Oncology in a research report on Thursday, April 4th. They set a “buy” rating and a $7.00 price objective for the company. Laidlaw began coverage on ZIOPHARM Oncology in a research report on Monday, April 1st. They set a “buy” rating and a $7.50 price objective for the company. Zacks Investment Research downgraded ZIOPHARM Oncology from a “buy” rating to a “hold” rating in a research report on Saturday, May 18th. Finally, HC Wainwright restated a “buy” rating and set a $5.50 price objective on shares of ZIOPHARM Oncology in a research report on Thursday, May 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $5.75.

The company has a quick ratio of 8.89, a current ratio of 8.89 and a debt-to-equity ratio of 0.01. The stock has a market cap of $847.18 million, a P/E ratio of -10.88 and a beta of 2.52.

ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. As a group, equities analysts expect that ZIOPHARM Oncology Inc. will post -0.3 EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the business. BlueCrest Capital Management Ltd purchased a new position in ZIOPHARM Oncology during the first quarter worth about $91,000. HighTower Advisors LLC boosted its holdings in shares of ZIOPHARM Oncology by 45.4% in the 1st quarter. HighTower Advisors LLC now owns 154,976 shares of the biotechnology company’s stock worth $595,000 after purchasing an additional 48,396 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of ZIOPHARM Oncology by 25.5% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 114,540 shares of the biotechnology company’s stock worth $441,000 after purchasing an additional 23,293 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of ZIOPHARM Oncology by 13.2% in the 1st quarter. Geode Capital Management LLC now owns 1,756,856 shares of the biotechnology company’s stock worth $6,763,000 after purchasing an additional 204,840 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of ZIOPHARM Oncology by 12.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 834,853 shares of the biotechnology company’s stock worth $3,215,000 after purchasing an additional 90,895 shares in the last quarter. Hedge funds and other institutional investors own 38.51% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2019/06/15/ziopharm-oncology-nasdaqziop-shares-gap-up-to-4-89.html.

ZIOPHARM Oncology Company Profile (NASDAQ:ZIOP)

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

Further Reading: Return On Assets

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.